Tazeen Ahmad, an analyst from Bank of America Securities, maintained the Buy rating on BioNTech SE. The associated price target remains the same with $134.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Tazeen Ahmad has given his Buy rating due to a combination of factors that highlight BioNTech SE’s strategic integration of artificial intelligence (AI) into its research and development, particularly in the oncology sector. The company’s AI Day 2025 showcased significant advancements in their InstaNovo proteomics platform and infrastructure investments like the Kyber supercomputer, which are expected to enhance their immunotherapy design and optimization capabilities. These innovations are seen as strengthening the long-term potential of BioNTech’s oncology franchise, with the potential to accelerate the development of novel assets and expand their mRNA vaccine platform.
Furthermore, BioNTech’s emphasis on AI-enabled tools for its infectious disease franchise is another reason for the Buy rating. The advancements in computational nanoparticle vaccine design and AI-assisted tissue annotation are expected to support next-generation vaccine development and streamline translational research. These capabilities are viewed as complementary to BioNTech’s existing efforts in COVID-19 vaccines and could aid in diversifying their portfolio into other infectious diseases, thereby enhancing long-term growth prospects.
In another report released on September 19, Clear Street also maintained a Buy rating on the stock with a $185.00 price target.
Based on the recent corporate insider activity of 29 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BNTX in relation to earlier this year.